Role of blood coagulation factor XIII in vascular diseases

Swiss Medical Weekly

Volumn 131, Issue 3-4, 2001, Pages 31-34

  Kohler, H P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; INSULIN; LEUCINE; VALINE;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DEEP VEIN THROMBOSIS; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; HEART INFARCTION; HUMAN; IN VITRO STUDY; INSULIN RESISTANCE; PATHOGENESIS; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN CROSS LINKING; PROTEIN STRUCTURE; SHORT SURVEY; SITE DIRECTED MUTAGENESIS; STROKE; STRUCTURE ACTIVITY RELATION; VASCULAR DISEASE;

EID: 0035098736     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (35)

1. Fibrin clots. Some properties of the "serum factor"
2. Transglutaminases: Multifunctional crosslinking enzymes that stabilize tissue
3. Factor V is a substrate for the transamidase factor XIIIa
4. Cross-linking site in fibrinogen for α-plasmin inhibitor
5. Cross-linking of fibronectin to collagen by blood coagulation factor XIIIa
6. Tissue transglutaminase and factor XIII in cartilage and bone remodeling
7. Human procarboxypeptidase U, or thrombin-activatable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin
8. B protein of factor XIII: Differentiation between free B and complexed B
9. Zur frage der reversibilität der fibringerinnung
10. Deficiency in the A-subunit of coagulation factor XIII: Two novel point mutations demonstrate different effects on tanscript levels
11. Molecular basis of inherited factor XIII deficiency: Identification of multiple mutations provides insights into protein function
12. Novel polymorphisms and haplotypes in the human coagulation factor XIII A-subunit gene
13. A common coding polymorphism in the factor XIII A-subunit gene (FXIII-Va134Leu) affects cross-linking activity
14. Effects of factor XIII Va134Leu on α-antiplasmin incorporation into fibrin
15. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIIIVa134Leu mutation
16. Association of a common polymorphism in the factor XIII gene with myocardial infarction
17. Prevalence of three common polymorphisms in the A-subunit gene of FXIII in patients with coronary artery disease. Association with FXIII activity and antigen levels
18. Association of FXIII Va134Leu with decreased risk of myocardial infarction in Finnish males
19. Factor XIII Va134Leu and the risk of myocardial infarction
20. Prevalence of FXIIIV34L in populations with different cardiovascular risk
21. Factor XIII Va134Leu: A novel association with primary intracerebral hemorrhage
22. The association between the Va134Leu polymorphism in the factor XIII gene and brain infarction
23. Association of a common polymorphism in the factor XIII gene with venous thrombosis
24. Prothrombin G20210A, factor V Leiden, and factor XIIIVa134Leu: Common mutations of blood coagulation factors and deep venous thrombosis in Austria
25. Factor XIIIVa134Leu is a genetic risk factor involved in the aetiology of venous thrombosis
26. Pathogenesis of primary pulmonary embolism: Impact of the FXIIIVa134Leu polymorphism
27. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age smoking, and hypertension
28. Factor XIII activity and antigen levels in patients with coronary artery disease. Interaction with FXIIIVa134Leu
29. Clustering of FXIIIVa134Leu with haemostatic risk factors
30. Levels of activated factor XII in survivors of myocardial infarction. Association with circulating risk factors and extent of coronary artery disease
31. FXII (46C→T) polymorphism and in vivo generation of FXII activity
32. Interaction between insulin resistance and factor XIIIVa134Leu in patients with coronary artery disease
33. Role of insulin resistance in human disease
34. Plasminogen activator inhibitor type 1 and coronary artery disease
35. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and their first-degree relatives